Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787333 | 0.78 | SMN1; SMN2 (0.45) | ALDH1A1KMT2ATP53SMN1; SMN2RAB9A | |
| SCHEMBL2772968 | 0.75 | SMN1; SMN2 (0.41) | ALDH1A1KMT2ATP53SMN1; SMN2CACNA1B | |
| SCHEMBL2767338 | 0.74 | KMT2A (0.52) | ALDH1A1KMT2ATP53SMN1; SMN2RAB9A | |
| SCHEMBL2769745 | 0.74 | RAB9A (0.43) | ALDH1A1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL2767332 | 0.73 | GAA (0.47) | ALDH1A1KMT2ATP53SMN1; SMN2RAB9A | |
| SCHEMBL2770798 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL2767526 | 0.71 | ALDH1A1 (0.53) | ALDH1A1KMT2ATP53SMN1; SMN2MEN1 | |
| SCHEMBL2771187 | 0.70 | SMN1; SMN2 (0.61) | ALDH1A1KMT2ATP53SMN1; SMN2MEN1 | |
| SCHEMBL2771566 | 0.70 | ALDH1A1 (0.50) | ALDH1A1KMT2ATP53SMN1; SMN2RAB9A | |
| SCHEMBL2768955 | 0.69 | MAOB (0.52) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881967-B1 | SUBSTITUTED BENZO(D)ISOXAZOL-3-YL AMINE COMPOUNDS AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1965/4885KMT2A 197/4885TP53 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.